Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of single intraprostatic NX-1207 injection for lower urinary tract symptoms due to benign prostatic hyperplasia
2012-002451-41Phase 3Completed
- Sponsor
- Recordati SpA
- Start
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of fexapotide triflutate in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Recordati SpA. Primary endpoint: Change from baseline in International Prostate Symptom Score total score. Started Mar 2013; status: completed.
02
Drugs
fexapotide triflutate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2012-002451-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002451-41.